• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用肽微阵列对治疗性抗体配方条件进行快速且信息丰富的分析。

Use of Peptide Microarrays for Fast and Informative Profiling of Therapeutic Antibody Formulation Conditions.

作者信息

Austerberry James, Edwards John, Eyes Tim, Derrick Jeremy P

机构信息

School of Biological Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester M13 9PT, United Kingdom.

出版信息

Mol Pharm. 2021 Nov 1;18(11):4131-4139. doi: 10.1021/acs.molpharmaceut.1c00543. Epub 2021 Oct 18.

DOI:10.1021/acs.molpharmaceut.1c00543
PMID:34658237
Abstract

Methods to optimize the solution behavior of therapeutic proteins are frequently time-consuming, provide limited information, and often use milligram quantities of material. Here, we present a simple, versatile method that provides valuable information to guide the identification and comparison of formulation conditions for, in principle, any biopharmaceutical drug. The subject protein is incubated with a designed synthetic peptide microarray; the extent of binding to each peptide is dependent on the solution conditions. The array is washed, and the adhesion of the subject protein is detected using a secondary antibody. We exemplify the method using a well-characterized human single-chain Fv and a selection of human monoclonal antibodies. Correlations of peptide adhesion profiles can be used to establish quantitative relationships between different solution conditions, allowing subgrouping into dendrograms. Multidimensional reduction methods, such as t-distributed stochastic neighbor embedding, can be applied to compare how different monoclonals vary in their adhesion properties under different solution conditions. Finally, we screened peptide binding profiles using a selection of monoclonal antibodies for which a range of biophysical measurements were available under specified buffer conditions. We used a neural network method to train the data against aggregation temperature, , percentage recovery after incubation at 25 °C, and melting temperature. The results demonstrate that peptide binding profiles can indeed be effectively trained on these indicators of protein stability and self-association in solution. The method opens up multiple possibilities for the application of machine learning methods in therapeutic protein formulation.

摘要

优化治疗性蛋白质溶液行为的方法通常耗时、提供的信息有限,且常常需要毫克级的材料量。在此,我们提出一种简单、通用的方法,该方法能提供有价值的信息,以指导原则上任何生物制药药物制剂条件的鉴定和比较。将目标蛋白质与设计好的合成肽微阵列一起孵育;与每种肽的结合程度取决于溶液条件。清洗该阵列,并用二抗检测目标蛋白质的黏附情况。我们以一种特征明确的人单链Fv和一系列人单克隆抗体为例对该方法进行了说明。肽黏附图谱的相关性可用于建立不同溶液条件之间的定量关系,从而进行聚类分析。可以应用多维降维方法,如t分布随机邻域嵌入,来比较不同单克隆抗体在不同溶液条件下黏附特性的差异。最后,我们使用一系列在特定缓冲条件下可获得多种生物物理测量数据的单克隆抗体筛选肽结合图谱。我们使用神经网络方法针对聚集温度、25℃孵育后的回收率百分比以及解链温度对数据进行训练。结果表明,肽结合图谱确实可以在这些蛋白质在溶液中的稳定性和自缔合指标上得到有效训练。该方法为机器学习方法在治疗性蛋白质制剂中的应用开辟了多种可能性。

相似文献

1
Use of Peptide Microarrays for Fast and Informative Profiling of Therapeutic Antibody Formulation Conditions.使用肽微阵列对治疗性抗体配方条件进行快速且信息丰富的分析。
Mol Pharm. 2021 Nov 1;18(11):4131-4139. doi: 10.1021/acs.molpharmaceut.1c00543. Epub 2021 Oct 18.
2
Physicochemical Stability of Monoclonal Antibodies: A Review.单克隆抗体的理化稳定性:综述。
J Pharm Sci. 2020 Jan;109(1):169-190. doi: 10.1016/j.xphs.2019.08.009. Epub 2019 Aug 26.
3
Application of interpretable artificial neural networks to early monoclonal antibodies development.可解释人工神经网络在早期单克隆抗体开发中的应用。
Eur J Pharm Biopharm. 2019 Aug;141:81-89. doi: 10.1016/j.ejpb.2019.05.017. Epub 2019 May 18.
4
The ReFOLD assay for protein formulation studies and prediction of protein aggregation during long-term storage.用于蛋白质配方研究和长期储存过程中蛋白质聚集预测的 ReFOLD 分析。
Eur J Pharm Biopharm. 2019 Apr;137:131-139. doi: 10.1016/j.ejpb.2019.02.018. Epub 2019 Feb 25.
5
The effect of formulation variables on protein stability and integrity of a model IgG4 monoclonal antibody and translation to formulation of a model ScFv.制剂变量对模型IgG4单克隆抗体的蛋白质稳定性和完整性的影响以及向模型单链抗体片段制剂的转化
Biotechnol Lett. 2018 Jan;40(1):33-46. doi: 10.1007/s10529-017-2443-x. Epub 2017 Sep 23.
6
Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies.一系列可开发治疗性单克隆抗体的热解折叠和聚集特性研究
Mol Pharm. 2015 Apr 6;12(4):1005-17. doi: 10.1021/mp400666b. Epub 2015 Feb 27.
7
The identification of affinity peptide ligands specific to the variable region of human antibodies.对人抗体可变区特异性亲和肽配体的鉴定。
Biomed Res. 2014;35(2):105-16. doi: 10.2220/biomedres.35.105.
8
Buffer-free therapeutic antibody preparations provide a viable alternative to conventionally buffered solutions: from protein buffer capacity prediction to bioprocess applications.无缓冲治疗性抗体制剂为传统缓冲溶液提供了一种可行的替代方案:从蛋白质缓冲容量预测到生物工艺应用。
Biotechnol J. 2015 Apr;10(4):610-22. doi: 10.1002/biot.201400531.
9
Application of ultraviolet, visible, and infrared light imaging in protein-based biopharmaceutical formulation characterization and development studies.应用于蛋白质类生物制药制剂特征分析和开发研究中的紫外光、可见光和红外光成象技术。
Eur J Pharm Biopharm. 2021 Aug;165:319-336. doi: 10.1016/j.ejpb.2021.05.013. Epub 2021 May 27.
10
Machine Learning Models of Antibody-Excipient Preferential Interactions for Use in Computational Formulation Design.用于计算制剂设计的抗体-辅料优先相互作用的机器学习模型
Mol Pharm. 2020 Sep 8;17(9):3589-3599. doi: 10.1021/acs.molpharmaceut.0c00629. Epub 2020 Aug 25.